Form 4: Haemonetics Corp Executive Stewart W. Strong Reports Stock Transactions

Stewart W. Strong, President of Global Hospital at Haemonetics Corp, reports acquisition and disposal of company stock, including shares from performance share units and sales under a 10b5-1 trading plan.

Summary

• On May 28, 2024, Stewart W. Strong acquired 13,256 shares of Haemonetics Corp common stock related to a performance share unit (PSU) award.
• Also on May 28, 2024, 4,399 shares were disposed of to cover tax obligations related to the vesting of the PSUs at a price of $95.73.
• On May 29, 2024, Strong sold 8,857 shares of common stock at a price of $87.53 per share.
• The sale on May 29, 2024 was executed under a pre-existing 10b5-1 trading plan dated June 12, 2023.
• Following these transactions, Strong directly owns 18,196 shares of Haemonetics Corp common stock, which includes unvested restricted stock units (RSUs).

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are part of normal executive compensation and pre-planned trading activity. The vesting of PSUs is a positive sign, but the subsequent sale is a neutral event given the 10b5-1 plan.

Positives

• The vesting of performance share units indicates that performance targets related to total shareholder return relative to the S&P MidCap 400 Index were met for the period from May 18, 2021 to May 17, 2024.

Negatives

• The sale of shares by an executive could be perceived negatively by some investors, although it was conducted under a pre-existing 10b5-1 trading plan.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create uncertainty in the market.

Industry Context

Executive stock transactions are a normal part of corporate governance. Monitoring these transactions provides insights into executive sentiment and alignment with shareholder interests. The use of 10b5-1 plans is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages often include performance-based equity awards like PSUs to align executive incentives with shareholder returns.
• The vesting of PSUs based on relative TSR performance against the S&P MidCap 400 Index is a common benchmark in the industry.
• Sales under 10b5-1 trading plans are a standard practice among corporate executives to manage their personal finances while avoiding insider trading concerns; companies like Medtronic and Boston Scientific also see regular 10b5-1 trading activity by their executives.

Stakeholder Impact

• Shareholders may view the vesting of PSUs positively as it indicates the achievement of performance targets.
• The subsequent sale of shares could be perceived neutrally or slightly negatively, depending on individual investor perspectives and understanding of 10b5-1 trading plans.

Key Dates